Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting
Aquestive Therapeutics (NASDAQ: AQST) announced a subsequent analysis of their pivotal study for Anaphylm™ (epinephrine) Sublingual Film to be presented at the ACAAI 2024 Annual Meeting. The analysis demonstrates that the film maintains consistent pharmacokinetics and pharmacodynamics regardless of placement or movement in the mouth.
The study showed that 87.5% of subjects had no change in film location between 1.5 to 3 minutes after administration. In cases where movement occurred (12.5% of subjects), there were no significant differences in drug concentration metrics. The geometric mean maximum concentration was 351.14 and 490.27 pg/mL for subjects with and without film movement, respectively, with a median peak drug concentration of 12 minutes for both groups.
Aquestive Therapeutics (NASDAQ: AQST) ha annunciato un'analisi successiva del loro studio fondamentale per Anaphylm™ (epinefrina) Film Sublinguale, che sarà presentata al Congresso Annuale ACAAI 2024. L'analisi dimostra che il film mantiene farmacocinetica e farmacodinamica costanti indipendentemente dalla posizione o dal movimento nella bocca.
Lo studio ha mostrato che il 87,5% dei soggetti non ha avuto cambiamenti nella posizione del film tra 1,5 e 3 minuti dopo la somministrazione. Nei casi in cui si è verificato movimento (il 12,5% dei soggetti), non ci sono state differenze significative nei parametri di concentrazione del farmaco. La concentrazione massima geometrica media era di 351,14 e 490,27 pg/mL per i soggetti con e senza movimento del film, rispettivamente, con una concentrazione di picco mediana del farmaco di 12 minuti per entrambi i gruppi.
Aquestive Therapeutics (NASDAQ: AQST) anunció un análisis posterior de su estudio pivotal para Anaphylm™ (epinefrina) Película Sublingual, que se presentará en la Reunión Anual ACAAI 2024. El análisis demuestra que la película mantiene una farmacocinética y farmacodinamia consistentes, independientemente de la colocación o movimiento en la boca.
El estudio mostró que el 87,5% de los sujetos no experimentó cambios en la ubicación de la película entre 1.5 a 3 minutos después de la administración. En los casos donde hubo movimiento (12.5% de los sujetos), no hubo diferencias significativas en los parámetros de concentración del fármaco. La concentración máxima geométrica media fue de 351.14 y 490.27 pg/mL para los sujetos con y sin movimiento de la película, respectivamente, con una concentración máxima mediana del fármaco de 12 minutos para ambos grupos.
Aquestive Therapeutics (NASDAQ: AQST)는 Anaphylm™ (에피네프린) 설하 필름에 대한 주요 연구의 후속 분석을 발표했으며, 이 내용은 ACAAI 2024 연례 회의에서 발표될 예정입니다. 분석 결과, 필름은 입안에서의 위치나 움직임에 관계없이 일관된 약리학적 활성 및 약동학을 유지함을 보여줍니다.
연구에 따르면 87.5%의 피험자는 투여 후 1.5에서 3분 사이에 필름 위치에 변화가 없었습니다. 이동이 발생한 경우(12.5%의 피험자)에도 약물 농도 지표에서 유의미한 차이는 없었습니다. 기하학적 평균 최대 농도는 필름 이동이 있는 피험자와 없는 피험자 각각 351.14 및 490.27 pg/mL였으며, 두 그룹 모두에서 약물의 중앙 피크 농도는 12분이었습니다.
Aquestive Therapeutics (NASDAQ: AQST) a annoncé une analyse subséquente de son étude pivot pour Anaphylm™ (épinéphrine) Film Sublingual, qui sera présentée à la Réunion Annuelle de l'ACAAI 2024. L'analyse démontre que le film maintient une pharmacocinétique et une pharmacodynamique constantes, quelle que soit la position ou le mouvement dans la bouche.
L'étude a montré que 87,5% des sujets n'avaient pas de changement de position du film entre 1,5 et 3 minutes après l'administration. Dans les cas où un mouvement a eu lieu (12,5% des sujets), il n'y avait pas de différences significatives dans les métriques de concentration du médicament. La concentration maximale moyenne géométrique était de 351,14 et 490,27 pg/mL pour les sujets avec et sans mouvement du film, respectivement, avec une concentration médiane de pic du médicament de 12 minutes pour les deux groupes.
Aquestive Therapeutics (NASDAQ: AQST) hat eine nachfolgende Analyse ihrer wegweisenden Studie zu Anaphylm™ (Epinephrin) Sublingualfilm angekündigt, die auf dem ACAAI-Jahrestreffen 2024 präsentiert wird. Die Analyse zeigt, dass der Film unabhängig von der Platzierung oder Bewegung im Mund eine konsistente Pharmakokinetik und Pharmakodynamik aufrechterhält.
Die Studie ergab, dass 87,5% der Probanden in den ersten 1,5 bis 3 Minuten nach der Verabreichung keine Veränderung der Filmlage aufwiesen. In Fällen, in denen Bewegung auftrat (12,5% der Probanden), gab es keine signifikanten Unterschiede in den Medikamentenkonzentrationswerten. Der geometrische Mittelwert der maximalen Konzentration betrug 351,14 und 490,27 pg/mL für Probanden mit und ohne Filmbewegung, wobei die mediane maximale Medikamentenkonzentration für beide Gruppen 12 Minuten betrug.
- None.
- None.
- Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection
- Data demonstrates Anaphylm offers a consistent and permissive method of drug delivery in anaphylaxis management
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm™ (epinephrine) Sublingual Film demonstrating comparable PK and PD data regardless of variable placement or intraoral movement will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which is being held from October 24-28 in Boston, Massachusetts.
"The poster, detailing a subsequent analysis of the data from the pivotal study of Anaphylm, being presented at ACAAI this year marks an important milestone in our development of Anaphylm, as it demonstrates the robustness and reliability of our sublingual film technology," said Dan Barber, Aquestive's President and Chief Executive Officer. "These findings show that our innovative PharmFilm™ delivery system maintains consistent pharmacokinetics and pharmacodynamics regardless of minor variations in placement, providing further evidence of Anaphylm's potential to offer healthcare providers and patients a dependable alternative for the treatment of severe allergic reactions. Anaphylm has the potential to be the first and only FDA-approved no-needle, no-device, oral epinephrine product for treating severe allergic reactions, including anaphylaxis, if approved by the FDA."
The poster presentation will showcase a subsequent analysis of the previously disclosed pivotal study that successfully met primary and secondary endpoints, found at the link here. The subsequent analysis was conducted to evaluate the impact of intraoral film placement and movement on variability in PK and PD. Movement was noted in
Presentation Details:
Abstract Title: Sublingual Epinephrine Film's Mucoadhesive Properties Ensures Consistent Oral Placement and Drug Release
Abstract ID: 8103
ePoster ID: R008
Presentation Time: Friday, October 25, 2024, 3:45 PM ET
Location: Monitor 16, Exhibit Hall A, Hynes Convention Center
The poster are available online for registered participants of the meeting at annualmeeting.acaai.org, and will also be available on the Events and Presentations page of the Investor Section of the Company's website following the presentation.
About Anaphylm™
Anaphylm™ (epinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. The Anaphylm trade name for AQST-109 has been conditionally approved by the FDA. Final approval of the Anaphylm proprietary name is conditioned on FDA approval of the product candidate.
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel for various dermatology conditions including Alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward-Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of our product candidate Anaphylm™ (epinephrine) Sublingual Film through clinical development and approval by the FDA, the potential benefits Anaphylm could bring to patients, and other statements that are not historical facts.
These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with our development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans, including those relating to Anaphylm (including for pediatric patients); risk of delays in advancement of the regulatory approval process through the FDA of our product candidates, including the filing of the respective NDAs, including for Anaphylm, or the failure to receive FDA approval at all of any of these product candidates; risk of the Company’s ability to generate sufficient clinical data for approval of our product candidates, including with respect to our PK and PD comparability submission for FDA approval of Anaphylm; risk of the Company’s ability to address the FDA’s comments on the Company’s clinical trials and other concerns identified in the FDA Type C meeting minutes for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm; risks and uncertainties inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of sufficient capital and cash resources, including sufficient access to available debt and equity financing, including under our ATM facility and the Lincoln Park Purchase Agreement, and revenues from operations, to satisfy all of our short-term and longer-term liquidity and cash requirements and other cash needs, at the times and in the amounts needed, including to fund commercialization activities relating to fund future clinical development and commercial activities for our product candidates, including Anaphylm, should these product candidates be approved by the FDA; risk of eroding market share for Suboxone® and risk as a sunsetting product, which accounts for the substantial part of our current operating revenue; risk of default of our debt instruments; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance in the U.S. of Anaphylm and our other product candidates, should these product candidates be approved by the FDA, and for our licensed products in the U.S. and abroad; risk of the success of any competing products including generics; risk of the size and growth of our product markets; risk of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to our products; risk that our patent applications for our product candidates, including for Anaphylm, will not be timely issued, or issued at all, by the U.S. Patent and Trademark Office; risk of unexpected patent developments; risk of legislation and regulatory actions and changes in laws or regulations affecting our business including relating to our products and products candidates and product pricing, reimbursement or access therefor; risk of loss of significant customers; risks related to claims and legal proceedings against Aquestive including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters; risk of product recalls and withdrawals; risks related to any disruptions in our information technology networks and systems, including the impact of cybersecurity attacks; risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements; risk of adverse developments affecting the financial services industry; risks related to inflation and rising interest rates; risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on our business, including with respect to our clinical trials and the site initiation, patient enrollment and timing and adequacy of those clinical trials, regulatory submissions and regulatory reviews and approvals of our product candidates, availability of pharmaceutical ingredients and other raw materials used in our products and product candidates, supply chain, manufacture and distribution of our products and product candidates; risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial and market conditions and other unusual items; and other uncertainties affecting us including those described in the "Risk Factors" section and in other sections included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.
Investor Inquiries:
ICR Healthcare
Stephanie Carrington
stephanie.carrington@icrhealthcare.com
646-277-1282
FAQ
What were the key findings of Aquestive's Anaphylm sublingual film study presented at ACAAI 2024?
How many subjects experienced film movement in the Anaphylm (AQST) pivotal study?
What is the potential significance of Anaphylm for AQST if approved by FDA?